Form 4: Iradimed Corp Insider Sells Shares Under 10b5-1 Plan

Iradimed Corp's CEO, Roger E. Susi, reported the sale of common stock totaling 7,527 shares across multiple transactions executed between May 4th and May 5th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, Chairman, and Director of Iradimed Corporation, executed a series of stock sales between May 4, 2026, and May 5, 2026.
• These transactions involved the sale of a total of 7,527 shares of common stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• The weighted average sale prices ranged from $83.42 to $87.40 per share.
• Following these transactions, Roger E. Susi's beneficial ownership of Iradimed Corp common stock is reported as 2,187,500 shares, held indirectly through various trusts and his revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions are standard insider sales conducted under a pre-established Rule 10b5-1 plan, indicating a planned divestment rather than a reaction to negative company performance.

Negatives

• Insider selling activity, even if conducted under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market.
• The total value of shares sold by Roger E. Susi amounts to approximately $640,000 based on the reported weighted average prices.

Risks

• The Rule 10b5-1 plan is intended to provide an affirmative defense against insider trading allegations, but its effectiveness relies on strict adherence to its terms and proper adoption.
• While the sales are part of a pre-planned strategy, significant insider selling could signal a lack of confidence in future stock performance, although this is not explicitly stated.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple transactions.

Industry Context

StockSavvy.ai notes that insider selling under Rule 10b5-1 plans is a common practice for executives to diversify holdings or manage personal finances without triggering insider trading concerns. However, the volume and timing of such sales can still influence market perception.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a 10b5-1 plan, as a potential signal, though the plan's existence mitigates direct insider trading concerns.
• Management: Demonstrates adherence to corporate governance best practices by utilizing a Rule 10b5-1 plan for stock transactions.

Next Steps

• The reporting person will continue to adhere to the terms of the Rule 10b5-1 trading plan.
• The company may provide further information regarding the transactions upon request from regulatory bodies or security holders.

Key Dates

Keywords

Iradimed Corp, IRMD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Roger E. Susi, Beneficial Ownership, Securities Exchange Act